Journal of vascular and interventional radiology : JVIR · 2026
Percutaneous Sclerotherapy Followed by Transabdominal Microwave Ablation for Treatment of Uterine Fibroids: A Prospective Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Hui-Li, Yao Yu, Li Jia-Xin, Zhu Jing-E, Xie Chen-Yi, Guo Jing, Yu Song-Yuan, Peng Cheng-Zhong, Sun Li-Ping
Аннотация
PURPOSE: To evaluate the clinical and technical effectiveness, treatment efficiency, and safety of ultrasound (US)-guided polidocanol sclerotherapy combined with transabdominal microwave ablation (MWA) for fibroids.
MATERIALS AND METHODS: Fifty-seven patients with 74 fibroids who underwent sclerotherapy combined with MWA treatment were included. Intraoperative contrast-enhanced US was used to assess sclerotherapy-induced vascular occlusion. Fibroid characteristics and ablation parameters were compared based on the vascular occlusion degrees (Grades 0-3). The nonperfusion volume ratio (NPVr) was calculated from magnetic resonance (MR) imaging. Follow-up at 3, 6, and 12 months evaluated symptom relief, uterine/fibroid volume, hemoglobin (Hb) level, pictorial blood loss assessment chart (PBAC) score, symptom severity score (SSS), and health-related quality of life (HRQOL) scores. Adverse events (AEs) were recorded.
RESULTS: The mean patient age was 42 years (interquartile range [IQR], 38-46 years). Complete, significant, slight, and failed occlusion rates were 48.6%, 39.2%, 6.8%, and 5.4%, respectively. The degree of occlusion was associated with fibroid classification, T2 signal intensity, and NPVr. Median NPVr was 98.5% (IQR, 88.3%-101.1%), and median ablation efficiency was 4.9 s/cm (IQR, 3.3-6.4 s/cm). At 12 months, the complete relief rates of menorrhagia, prolonged menses, anemia, frequent micturition, and pelvic discomfort were 76.9%, 66.7%, 71.4%, 61.9%, and 68.8%, respectively. Uterine and fibroid volume decreased significantly, with improvement in Hb levels, PBAC, SSS, and HRQOL scores. No moderate or worse AEs occurred.
CONCLUSIONS: US-guided sclerotherapy followed by MWA appears to be a practical, efficient, and safe treatment for fibroids.
MATERIALS AND METHODS: Fifty-seven patients with 74 fibroids who underwent sclerotherapy combined with MWA treatment were included. Intraoperative contrast-enhanced US was used to assess sclerotherapy-induced vascular occlusion. Fibroid characteristics and ablation parameters were compared based on the vascular occlusion degrees (Grades 0-3). The nonperfusion volume ratio (NPVr) was calculated from magnetic resonance (MR) imaging. Follow-up at 3, 6, and 12 months evaluated symptom relief, uterine/fibroid volume, hemoglobin (Hb) level, pictorial blood loss assessment chart (PBAC) score, symptom severity score (SSS), and health-related quality of life (HRQOL) scores. Adverse events (AEs) were recorded.
RESULTS: The mean patient age was 42 years (interquartile range [IQR], 38-46 years). Complete, significant, slight, and failed occlusion rates were 48.6%, 39.2%, 6.8%, and 5.4%, respectively. The degree of occlusion was associated with fibroid classification, T2 signal intensity, and NPVr. Median NPVr was 98.5% (IQR, 88.3%-101.1%), and median ablation efficiency was 4.9 s/cm (IQR, 3.3-6.4 s/cm). At 12 months, the complete relief rates of menorrhagia, prolonged menses, anemia, frequent micturition, and pelvic discomfort were 76.9%, 66.7%, 71.4%, 61.9%, and 68.8%, respectively. Uterine and fibroid volume decreased significantly, with improvement in Hb levels, PBAC, SSS, and HRQOL scores. No moderate or worse AEs occurred.
CONCLUSIONS: US-guided sclerotherapy followed by MWA appears to be a practical, efficient, and safe treatment for fibroids.
Предметные рубрики MeSH
HumansFemaleLeiomyomaSclerotherapyAdultMiddle AgedTreatment OutcomeUterine NeoplasmsProspective StudiesMicrowavesSclerosing SolutionsPolidocanolQuality of LifeUltrasonography, InterventionalTime FactorsPolyethylene GlycolsAblation TechniquesCombined Modality TherapyMagnetic Resonance ImagingTumor Burden